

Supplemental Figure 1 – CALGB10403 Schema⁵

Remission Induction (Course I)

Allopurinol –300 mg/day (unless allergic) to continue until peripheral blasts and extramedullary disease are reduced

IT-Ara-C – Ara-C 70 mg IT on D 1.

Pred –60 mg/m²/day PO or IV in two divided doses on D1-28

VCR –1.5 mg/m² (max 2 mg) IV on D 1, 8, 15, and 22

DNR –25 mg/m² IV on D 1, 8, 15, and 22

PEG –2500 IU/m² IM or IV **D 4**

IT-MTX - 15 mg IT on D 8 & D 29 (also administered on D 15 and 22 for CNS3 patient)

Extended Remission Induction (if required) (Course IA)

Pred –60 mg/m²/day PO or IV (methylprednisolone) in two divided doses on D 1-14

DNR –25 mg/m² IV on D 1

VCR – Vincristine 1.5 mg/m² (maximum 2 mg) IV on D 1 and 8

PEG –2500 IU/m² IM or IV D 4

Remission Consolidation (Course II)

CTX –1000 mg/m² IV on D 1 & 29

Ara-C –75 mg/m² IV or SC on D 1-4, 8-11, 29-32, and 36-39

6-MP –60 mg/m² PO on D 1-14 and 29-42

VCR –1.5 mg/m² (maximum 2 mg) IV on D 15, 22, 43 and 50

PEG –2500 IU/m² IM or IV on D 15 and 43

IT-MTX - 15 mg IT on D 1, 8, 15 and 22 (omit does on D 15 &22 for CNS3 patients)

Interim Maintenance (Course III)

IV-MTX –starting dose 100 mg/m² IV (escalate by 50 mg/m² /dose on D 1, 11, 21, 31 and 41

PEG –2500 IU/m² IM or IV on D.2 and 22

IT-MTX - 15 mg IT on D 1 and 31

Delayed Intensification (Course IV)

VCR – 1.5 mg/m² (max 2 mg) IV on D 1, 8, 43, and 50

DEX – 10 mg/m² PO (or IV) divided BID on D 1-7 and 15-21

PEG –2500 IU/m² IM or IV D 4 (OR D 5 OR D 6) and D 43

CTX –1000 mg/m² IV on D 29

Ara-C –75 mg/m² IV or SC on D 29-32 and 36-39

6-TG –60 mg/m²/day PO on D 29-42

IT-MTX - 15 mg IT on D 1, 29, & 36

Maintenance (Course V)*

VCR—1.5 mg/m² (maximum dose 2 mg) IV on D 1, 29, and 57

DEX—6 mg/m²/day PO (or IV) divided BID every 4 weeks on D 1-5, 29-33, and 57-61

6-MP—75mg/m²/day PO on D 1-84

IT-MTX - 15 mg IT on D 1 (also is given on D 29 of the first 4 courses of maintenance)

PO-MTX —20 mg/m² PO weekly on D 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (held on D 29 of the first 4 courses of maintenance)

*Maintenance therapy consists of 12 week courses and continues until 3 years from initiation of Interim Maintenance for males (2 years for females)

*Patients with T-precursor ALL received 24 Gy prophylactic cranial irradiation during the first cycle of Maintenance therapy. Patients with CNS involvement at presentation received 18 Gy,

D: day, Pred: Prednisone, VCR: Vincristine, DNR: Daunorubicin, PEG: Peg-

Asparaginase, MTX: Methotrexate, CTX: Cyclophosphamide, Ara-C: Cytarabine, 6MP:

6-Mercaptopurine, 6-TG: Thioguanine, DEX: Dexamethasone